We studied killer-cell Ig-like receptor (KIR)/natural killer (NK)-cell group-2-Ag repertoires on donor-derived NK cells in 28 patients after haploidentical SCT in the first 6 months after SCT and correlated results with EFS. The reconstitution hierarchy of potentially alloreactive, single KIR þ NK cells was the following: HLA-C1 binding4 HLA-Bw4 binding4HLA-C2 binding. The differences in reconstitution kinetics of the three potentially alloreactive NK cell subsets prompted an updated analysis of EFS in AML patients transplanted from haploidentical donors in our center. This analysis showed that in haploidentical transplantation for AML, HLA-C group 1 mismatching in the graft vs host direction not only provides a survival advantage over non-NK-alloreactive (KIR ligandmatched) transplants (5-year EFS 67 ± 10% vs 17 ± 5%) but, indeed, also provides the best EFS compared with C2 (35 ± 10%) or Bw4 KIR ligand mismatches (44 ± 17%).
Introduction
Haploidentical SCT offers a treatment choice for patients with acute leukemia lacking a fully histocompatible donor. Disparities in HLA haplotypes often include killer Ig-like receptor (KIR) ligand mismatches in the graft vs host (GvH) direction, leading to the generation of donor-derived NK cells with antileukemic activity.
Donor vs recipient NK cell alloreactivity improved the outcomes of HLA haplotype-mismatched hematopoietic stem cell transplants [1] [2] [3] [4] [5] and of mismatched cord blood transplants 6 by controlling relapse of acute leukemia without causing GVHD.
Donor vs recipient NK cell alloreactivity is exerted by NK cells, which express inhibitory KIR for self-class I ligand(s). They sense the missing expression of donor KIR ligand(s) in the recipient and mediate alloreactions. Consequently, donor selection relies on HLA typing to identify the family member who expresses the class I group(s) which is/are missing in the recipient. These criteria are based on information that KIR2DL1 recognizes HLA-C group 2 alleles (C2) and KIR2DL2/KIR2DL3 recognize HLA-C group 1 alleles (C1). KIR3DL1 recognizes HLA-Bw4 alleles. Thus, the three KIR ligand mismatches (in the GvH direction) which trigger donor vs recipient NK cell alloreactivity are as follows: (1) HLA-C1 present in the donor/missing in the recipient, (2) HLA-C2 present in the donor/missing in the recipient and (3) HLABw4 present in the donor/missing in the recipient.
Direct identification of donor vs recipient alloreactive NK cells in the donor and their posttransplant reconstitution are assessed by limiting dilution cloning and cytotoxicity assays against recipient target cells. In this study, we used flow cytometry to monitor reconstitution of potentially alloreactive, single KIR-expressing NK cells in a cohort of 28 patients in the first 6 months after haploidentical SCT.
Materials and methods

Transplant regimen and KIR ligand status
Patients were conditioned with TBI (8 Gy; day À9), thiotepa (5 mg/kg per day on days À8, À7), fludarabine (40 mg/m 2 per day on days À7 through À3) and rabbit antithymocyte globulin (5 mg/kg per day on days À5 through À2). Granulocyte CSF-mobilized hematopoietic progenitor cells were transplanted after Clinimacs CD34 þ cell selection (Miltenyi Biotec, Bergisch Gladbach, Germany). No pharmacological GVHD prophylaxis was administered. 3 In all, 13 patients received donor lymphocyte infusions and 3 patients mesenchymal stromal cell infusions after transplant. Four patients developed GVHD and were treated with steroids. All patients were treated on protocols approved by the Umbria Region Ethics Committee and the Perugia University institutional review board. Informed consent for treatment and analysis of outcome data was provided in accordance with the Declaration of Helsinki. Flow cytometry KIR/NKG2A repertoires were studied in donors and in patients at 4, 6, 8, 12 and 24 weeks after haploidentical SCT. Frequencies of donor-derived NK cell subsets binding HLA-C1, HLA-C2 or HLA-Bw4 were measured by multiparameter flow cytometry identification of KIR2DL/ S1 þ , KIR2DL/S2/L3À, KIR3DL/S1À, NKG2AÀ NK cells; KIR2DLS1À, KIR2DL/S2/L3 þ , KIR3DL/S1À, NKG2AÀ NK cells, KIR2DL/S1À, KIR2DL/S2/L3À, KIR3DL/S1 þ , NKG2AÀ NK cells, as well as overall KIR expression on NK cells. Non-NK cells were excluded by gating on CD56 þ /CD3À cells or by analyzing RosetteSep-purified NK cells (Stem Cell Technologies, Vancouver, BC, Canada).
Statistical analyses
Frequencies of NK sub-populations in transplant recipients were compared by t-test with those found in respective donors and a pool of 54 healthy unrelated donors, and by ANOVA (analysis of variance) within the three specificities. The influence of donor and recipient KIR ligand status and of infused CD34 cell dose on reconstitution of NK cell subsets was analyzed in multivariate regression models. EFS was calculated by Kaplan-Meier estimator, and the effect of KIR-ligand mismatching was evaluated in multivariable Cox models adjusting for disease stage at the time of transplant.
Results and Discussion
A representative example of reconstitution of a potentially alloreactive NK cell subset is shown in Figure 1 . In this example, the donor possessed C1 (the ligand for KIR2DL2 and/or KIR2DL3), which was missing in the recipient. This donor possessed the KIR2DL3 C1-specific receptor. As early as 4 weeks after transplant, the frequencies of KIR2DL3 þ NK cells in the recipient had reached donor levels. The potentially alloreactive KIR2DL3 þ /KIR2DL1À/KIR3DL1À/NKG2AÀ subset was smaller because of coexpression of other inhibitory receptors, mainly represented by NKG2A (495% of NK cells at this early time point as shown in Figure 2a ). This subset slowly expanded during follow-up due to decreasing (co)expression of NKG2A. Figure 2b shows the evolution of single KIR and total KIR expression in patients over time. At 4 weeks after (Figure 2 ). Comparing single KIR-expressing cell frequencies between the three specificities showed that differences were statistically significant (Po0.05) at all time points analyzed up to 6 months after transplantation. The reconstitution hierarchy of potentially alloreactive, single KIR þ NK cells was thus the following: HLA-C1 binding4HLA-Bw4 binding4HLA-C2 binding, a pattern that was observed when both relative and absolute numbers of NK cells were analyzed (Figures 2b and c) . This reconstitution pattern concurs with the in vitro pattern of KIR acquisition kinetics from hematopoietic precursor cells. 7, 8 In multivariable analyses, the presence of KIR ligand status did not show a statistically significant influence at any time point. After correction for the type of KIR involved, at week 4, we found a statistical trend toward higher frequencies of single KIR-expressing cells in patients with a KIR ligand mismatch in the GvH direction compared with patients receiving grafts that were KIR ligand matched or KIR ligand mismatched in the host vs graft direction (P ¼ 0.09). At all other time points and when analyzing total KIR expression, no significant influence of KIR ligands on NK cell subset reconstitution was found (P40.2). Neither the quantity of infused CD34-expressing cells (median 13.4, range 7.1-23.7 Â 10e6 per kg) nor T-cell reconstitution had an influence on single or global KIR expression at any time point (data not shown).
The differences in reconstitution kinetics of the three, potentially alloreactive NK cell subsets prompted an updated analysis of EFS in the 112 AML patients transplanted from haploidentical donors that we previously published. 3 EFS after transplantation from NK-alloreactive donors (51/112) according to which donor KIR ligand was missing in the recipient were as follows: 67 ± 10% for Table 1) .
The donor/recipient pairing criteria were challenged by the recent discovery that KIR2DL2/3 were specific not only for C1 but also bind with lower avidity to C2 ligands, 9 thus raising the question of whether C1 KIR ligand mismatching exerts a GvL effect. However, consistent with functional analyses using cloned NK cells which showed that high frequencies of NK cells from C1-positive donors kill C1-missing targets, 3 the present data show that in clinical transplantation for AML, HLA-C1 mismatching in the GvH direction, not only provides a survival advantage over non-NK-alloreactive (KIR ligand matched) transplants but, indeed, also provides the best EFS compared with C2 or Bw4 KIR ligand mismatches.
In conclusion, we show that KIR repertoire acquisition is skewed in the first 6 months after haploidentical SCT, with low numbers of NK cells expressing a single KIR in the absence of other KIR and NKG2A. Comparison of the three main KIR receptors shows a hierarchy with which single KIR þ NK cells arise: KIR2DL/S2/3 (C1-binding) singlepositive NK cells are consistently the first subset to appear at appreciable numbers, followed by KIR3DL/S1 (Bw4-binding) and finally KIR2DL/S1 (C2-binding) single-positive NK cells. Analysis of transplant outcomes suggests that the benefit of a KIR ligand mismatch is inversely related to the velocity with which a single KIR þ subset arises, that is, patients benefit most if transplanted from a donor with a ligand mismatch on a KIR that reconstitutes with a single KIR-expressing subset early after transplantation. 
